Journal of Multiple Sclerosis

Unveiling the Role of the Fungal Microbiome in Multiple Sclerosis: A Fresh Perspective

Shailen Maes^* and Jennie Lucifer ^*Correspondence: Shailen Maes, Student Research Committee, Faculty of Medicine CCS University of Medical Sciences, Iran, Email:

Author info »

Introduction

Scientists have been studying these tiny gut residents using special techniques that don't require growing them in a lab for about twenty years now. They've found that in diseases like Multiple Sclerosis (MS), there's something not quite right with the mix of bacteria in the gut. But until recently, most of this research has only looked at bacteria, ignoring the fungi and viruses that also live there.

Now, a new study by Shah and their team has looked at the fungi part of the gut community, called the mycobiome, in people with MS. They found that the fungal makeup in these individuals is different from those without MS. This study, along with another one by Yadav and their team (which hasn't been published yet but is available for others to see), suggests that fungi might play a big role in MS.

Shat and colleagues looked at the fungal communities (mycobiomes) in 25 people with Multiple Sclerosis (MS) and 22 healthy individuals [1-3]. They found that those with MS had more types of fungi in their bodies compared to the healthy group, and this didn't change much over six months. Some specific fungi, like Saccharomyces and Aspergillus, were more common in people with MS. Surprisingly, treatments for MS that fight fungi didn't seem to change the types of fungi present.

The researchers sorted the fungal profiles into two groups, or "mycotypes." Mycotype 1 had a lot of Saccharomyces, while Mycotype 2 had more variety, including Penicillium, Malassezia, Mucor, and Saccharomyces. They also found that Saccharomyces was linked to higher levels of certain immune cells.

These findings suggest that changes in fungal communities might play a role in MS and its severity. This idea is supported by past research showing different fungal patterns in people with other diseases like inflammatory bowel disease, cancer, heart disease, diabetes, obesity, and liver problems caused by alcohol.

Similar to bacteria, fungi are suggested to have a significant (symbiotic) role in maintaining immune balance at mucosal surfaces by regulating both innate and adaptive immunity. Recognition of fungi by innate immune receptors like Dectin-1, Dectin-2, C-type lectin receptors, and macrophage-inducible Ca2+-dependent lectin receptor helps modulate immune responses in the gut. Moreover, certain fungi such as Candida and Malassezia are potent stimulators of a systemic Th17 response and facilitate the expansion of the neutrophil population [4-6]. Recent studies underscore the importance of the mycobiome in T-cell activation and granulocyte expansion. These studies reveal that the mycobiome was enriched in the offspring of wild mice that received embryos from laboratory mice, or in laboratory mice reintroduced to the wild. It's noteworthy that laboratory mice, unlike humans, have lower numbers of activated T-cells and polymorphonuclear lymphocytes in their blood. These findings suggest that the absence of complex commensal fungi in mice could account for these differences in immune parameters.

The study discussed here faces limitations due to its small sample size, the classification of fungi at a low resolution, and the lack of a validation cohort of patients. It's notable that Candida and Saccharomyces are among the most abundant fungi in the human mycobiome, which makes the significantly reduced abundance of Candida observed in this study surprising. Various human studies have indicated a relatively higher abundance of Candida in both healthy individuals and patients with certain diseases such as inflammatory bowel disease, atherosclerosis, and type 2 diabetes mellitus. Additionally, higher Candida levels have been observed in individuals with Multiple Sclerosis (pwMS) compared to healthy controls using marker-based fungal classification. The lower Candida levels observed in the current study could be attributed to factors such as geographic location, lifestyles, dietary habits, or the bioinformatics pipeline utilized. Moreover, Saccharomyces has been linked to both a healthy mycobiome and certain diseases, suggesting either a strain-specific role of Saccharomyces in disease promotion or the influence of the overall composition of the mycobiome, including the bacterial microbiome, on its disease-protective or promoting properties [4,7]. Further exploration into the correlation between the abundance of Saccharomyces and Candida with other components of the microbiome in the context of multiple sclerosis is warranted [8].

An important next step in understanding how fungi might contribute to either protecting against or promoting disease is to conduct further research [9]. In conclusion, this study offers initial evidence that the fungal portion of the microbiome is disturbed in individuals with Multiple Sclerosis (pwMS). This sets the stage for future investigations aimed at characterizing the mycobiome in disease contexts using shotgun metagenomic sequencing and larger sample sizes [10]. Integrating these approaches with mechanistic studies will be crucial in elucidating the precise role of fungi in the pathobiology of multiple sclerosis.

References

1. Lynch, Susan V., and Oluf Pedersen. "The human intestinal microbiome in health and disease." N Eng J Med 375.24 (2016): 2369-2379.

   [Google Scholar] [Crossreff]

2. Freedman, Samantha N., Shailesh K. Shahi, and Ashutosh K. Mangalam. "The “gut feeling”: breaking down the role of gut microbiome in multiple sclerosis." Neurotherapeutics 15.1 (2018): 109-125.

   [Google Scholar] [Crossref]

3. Saumya S, et al. Alterations of the gut mycobiome in patients with MS" EBioMedicine 71 (2021).

   [Google Scholar] [Crossref]

4. Yadav, Meeta, et al. "Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness." PLoS One 17.4 (2022).

   [Google  Scholar] [Crossref]

5. Chin, Voon Kin, et al. "Mycobiome in the gut: a multiperspective review." Mediat Inflamm 2020 (2020).

   [Google Scholar] [Crossref]

6. Gutierrez, Mackenzie W., and Marie-Claire Arrieta. "The intestinal mycobiome as a determinant of host immune and metabolic health." Curr Opin Microbiol 62 (2021): 8-13.

   [Google Scholar] [Crossref]

7. Sparber, Florian, Fiorella Ruchti, and Salomé LeibundGut-Landmann. "Host immunity to Malassezia in health and disease." Front Cell Infect Microbiol 10 (2020): 198.

   [Google Scholar] [Crossref]

8. Rosshart, Stephan P., et al. "Laboratory mice born to wild mice have natural microbiota and model human immune responses." Science 365.6452 (2019)

   [Google Scholar] [Crossref]

9. Yeung, Frank, et al. "Altered immunity of laboratory mice in the natural environment is associated with fungal colonization." Cell Host Microbe 27.5 (2020): 809-822.

   [Google Scholar] [Crossref]

10. Nash, Andrea K., et al. "The gut mycobiome of the Human Microbiome Project healthy cohort." Microbiome 5 (2017): 1-13.

    [Google Scholar] [Crossref]